AR074561A1 - Formas cristalinas de un inhibidor de 11-beta-hidroxiesteroide deshidrogenasa del tipo 1 - Google Patents

Formas cristalinas de un inhibidor de 11-beta-hidroxiesteroide deshidrogenasa del tipo 1

Info

Publication number
AR074561A1
AR074561A1 ARP090104764A ARP090104764A AR074561A1 AR 074561 A1 AR074561 A1 AR 074561A1 AR P090104764 A ARP090104764 A AR P090104764A AR P090104764 A ARP090104764 A AR P090104764A AR 074561 A1 AR074561 A1 AR 074561A1
Authority
AR
Argentina
Prior art keywords
type
beta
inhibitor
crystal forms
hydroxiesteroid
Prior art date
Application number
ARP090104764A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR074561A1 publication Critical patent/AR074561A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Para el tratamiento de afecciones asociadas con el síndrome metabólico así como el deterioro cognitivo. También se refiere a composiciones farmacéuticas, a procesos para preparar, usos de las mismas para el tratamiento de diabetes del Tipo 2, hiperglucemia, obesidad, dislipidemia, hipertensión y deterioro cognitivo. Reivindicación 1 3-[4-(3-etanosulfonil-propil)-biciclo[2.2.2]oct-1-il]-4-metil-5-(2-trifluorometil-fenil)-4H-1,2,4-triazol de fórmula estructural (1) caracterizado por se un anhidrato cristalino.
ARP090104764A 2008-12-12 2009-12-09 Formas cristalinas de un inhibidor de 11-beta-hidroxiesteroide deshidrogenasa del tipo 1 AR074561A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12199408P 2008-12-12 2008-12-12

Publications (1)

Publication Number Publication Date
AR074561A1 true AR074561A1 (es) 2011-01-26

Family

ID=41667509

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104764A AR074561A1 (es) 2008-12-12 2009-12-09 Formas cristalinas de un inhibidor de 11-beta-hidroxiesteroide deshidrogenasa del tipo 1

Country Status (8)

Country Link
US (1) US8618112B2 (es)
EP (1) EP2376460A1 (es)
JP (2) JP5872290B2 (es)
AR (1) AR074561A1 (es)
AU (1) AU2009324810B2 (es)
CA (1) CA2745882A1 (es)
TW (1) TW201026670A (es)
WO (1) WO2010068580A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3263484A (en) * 1962-04-04 1966-08-02 Perkin Elmer Corp Differential microcalorimeter
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors

Also Published As

Publication number Publication date
JP2015164931A (ja) 2015-09-17
JP2012511576A (ja) 2012-05-24
WO2010068580A1 (en) 2010-06-17
TW201026670A (en) 2010-07-16
AU2009324810B2 (en) 2015-05-14
US20110237634A1 (en) 2011-09-29
CA2745882A1 (en) 2011-06-06
EP2376460A1 (en) 2011-10-19
US8618112B2 (en) 2013-12-31
JP5872290B2 (ja) 2016-03-01
AU2009324810A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
NO20084318L (no) Inhibitorer av II-beta-hydroksystereoid dehydrogenase I
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
PE20090762A1 (es) Compuestos organicos
DK2021337T3 (da) Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
PE20120018A1 (es) Composicion farmaceutica de linagliptina y 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, forma farmaceutica y procedimiento para su preparacion
DK2035379T3 (da) Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
AR064777A1 (es) Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
CL2008000422A1 (es) El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.
NO20084403L (no) Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
DOP2012000006A (es) Agonista de gpr119
PE20140244A1 (es) Composicion farmaceutica, metodos de tratamiento y usos de la misma
CR9931A (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
BR112013016982A2 (pt) formas polimórficas de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acético e usos destes
CL2009000953A1 (es) Compuestos derivados de 2-imino-3-metil-pirrolo pirimidinona, composicion farmaceutica, util para inhibir la beta-secretasa, destinado al tratamiento de la enfermedad de alzheimer, sindrome de down, parkinson, perdida de la memoria, demencia, accidente cerebrovascular, microgliosis e inflamacion cerebral, glaucoma amiloidosis, diabetes tipo ii, entre otras.
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
DK2049513T3 (da) Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
PE20081897A1 (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
EA200870462A1 (ru) Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
PE20080252A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
EA201270676A1 (ru) Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3- илтио)ацетата натрия и их применение
CL2007001597A1 (es) Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes

Legal Events

Date Code Title Description
FB Suspension of granting procedure